Market Cap N/A
Revenue (ttm) 230,000.00
Net Income (ttm) -6.66M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 656
Avg Vol 15,748
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 41%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Latest News on LEXXW
Lexaria announces dosing completion in 2026 Animal Study 2

2026-06-09T13:34:05.000Z - 7 days ago

Lexaria announces dosing completion in 2026 Animal Study 2


Lexaria Bioscience Slides: Corporate presentation

May 27, 2026, 7:00 AM EDT - 20 days ago

Lexaria Bioscience Slides: Corporate presentation


Lexaria Bioscience provides update on Human Pilot Study #7

2026-05-05T13:24:25.000Z - 6 weeks ago

Lexaria Bioscience provides update on Human Pilot Study #7

NVO


Lexaria Updates Progress on Human Study #7

May 5, 2026, 9:10 AM EDT - 6 weeks ago

Lexaria Updates Progress on Human Study #7


Lexaria Bioscience provides update on GLP-1 oral pill market

2026-04-21T15:02:42.000Z - 2 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market


Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

2026-04-15T13:24:10.000Z - 2 months ago

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study


Lexaria Bioscience Quarterly report: Q2 2026

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Lexaria Bioscience Quarterly report: Q2 2026


Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

Apr 7, 2026, 9:10 AM EDT - 2 months ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval


Lexaria Bioscience to begin new human clinical study in GLP-1

2026-04-01T13:26:48.000Z - 2 months ago

Lexaria Bioscience to begin new human clinical study in GLP-1


Lexaria to Begin New Human Clinical Study in GLP-1

Apr 1, 2026, 9:20 AM EDT - 2 months ago

Lexaria to Begin New Human Clinical Study in GLP-1


Lexaria's Robust Patent Portfolio Continues to Grow

Mar 26, 2026, 9:20 AM EDT - 2 months ago

Lexaria's Robust Patent Portfolio Continues to Grow


Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Mar 24, 2026, 9:15 AM EDT - 3 months ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry


Lexaria Bioscience announces 2026 R&D plans

2026-03-04T14:39:22.000Z - 3 months ago

Lexaria Bioscience announces 2026 R&D plans


Lexaria Announces New R&D Plans for 2026

Mar 4, 2026, 9:25 AM EST - 3 months ago

Lexaria Announces New R&D Plans for 2026


Lexaria announces final results from GLP-1-H25-5 study

2026-02-05T14:25:56.000Z - 4 months ago

Lexaria announces final results from GLP-1-H25-5 study


Lexaria Bioscience awarded six additional patents

2026-01-22T14:25:16.000Z - 5 months ago

Lexaria Bioscience awarded six additional patents


Lexaria Awarded Six Additional Patents

Jan 22, 2026, 9:20 AM EST - 5 months ago

Lexaria Awarded Six Additional Patents


Lexaria Bioscience Quarterly report: Q1 2026

Jan 13, 2026, 7:00 AM EST - 5 months ago

Lexaria Bioscience Quarterly report: Q1 2026


Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 5 months ago

Lexaria Releases Annual Letter from the CEO


Lexaria Bioscience Registration statement: Registration filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Lexaria Bioscience Registration statement: Registration filing


Lexaria Bioscience Proxy statement: Proxy filing

Dec 10, 2025, 7:00 AM EST - 6 months ago

Lexaria Bioscience Proxy statement: Proxy filing


Lexaria Bioscience Registration statement: Registration filing

Dec 5, 2025, 7:00 AM EST - 6 months ago

Lexaria Bioscience Registration statement: Registration filing


Lexaria Bioscience Annual report: Q4 2025

Nov 28, 2025, 7:00 AM EST - 7 months ago

Lexaria Bioscience Annual report: Q4 2025


Lexaria Bioscience Registration statement: Registration filing

Oct 14, 2025, 8:00 AM EDT - 8 months ago

Lexaria Bioscience Registration statement: Registration filing


Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 8 months ago

Lexaria Bioscience Corp. Provides Strategic Update


GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 11 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies


Lexaria Bioscience Quarterly report: Q3 2025

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q3 2025


Lexaria Bioscience Quarterly report: Q2 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q2 2025


Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 1 year ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4


Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Lexaria's Human GLP-1 Study #5 Begins Dosing